Karyopharm Therapeutics Q2 2026 Earnings Report

Karyopharm Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.31
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Karyopharm Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $33.12 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Karyopharm Therapeutics Announcement Details

• Quarter: Q2 2026
• Date: 8/10/2026
• Time: Before Market Opens
• Conference Call Date: Monday, August 10, 2026
• Conference Call Time: 8:00AM ET

Karyopharm Therapeutics (NASDAQ:KPTI) (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways. The company conducts clinical trials both domestically and internationally, working with regulatory agencies in the United States and Europe. Through strategic collaborations, Karyopharm seeks to expand the therapeutic reach of its SINE technology into other areas of oncology and potentially neurodegenerative diseases.

Karyopharm is led by Michael Kauffman, M.D., President and Chief Executive Officer, who co-founded the company and has guided its transition from preclinical research to commercial-stage operations. Under his leadership, Karyopharm has forged partnerships with global pharmaceutical firms to advance pipeline candidates and ensure broader patient access. The company maintains a scientific advisory board composed of experts in cancer biology, translational medicine and drug development.